 |
市場調查報告書
商品編碼
1150065
肝癌的全球市場 - 市場佔有率·規模·趨勢·產業分析:各類型，各治療類型，各地區，市場區隔預測(2022年～2030年)Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030 |
||||||
全球肝癌的市場規模在2030年前將達到104億8,000萬美元。
本報告提供全球肝癌市場調查，提供市場概要，市場規模和預測，趨勢，促進因素·阻礙因素，各類型·各治療類型·各地區等分析，再加上企業簡介等資訊。
目錄
第1章 簡介
- 報告的說明
- 調查的目的
- 市場範圍
- 前提條件
- 利害關係者
第2章 摘要整理
- 市場概況
第3章 調查手法
- 概要
- 資料探勘
- 資訊來源
- 一次資訊
- 二次資訊
第4章 全球肝癌市場洞察
- 肝癌市場 - 產業的概述
- 肝癌市場動態
- 促進因素和機會
- 阻礙因素與課題
- 波特的五力分析
- 供給企業談判力
- 新加入廠商者的威脅
- 買方議價能力
- 替代品的威脅
- 現有企業間的競爭力
- 大環境分析
- 肝癌產業趨勢
- 價值鏈分析
- COVID-19影響分析
第5章 全球肝癌市場:各類型
- 主要調查結果
- 簡介
- 全球肝癌，各類型(2018年～2030年)
- 肝細胞癌症
- 全球肝癌市場，肝細胞癌症，各地區(2018年～2030年)
- 膽管癌症
- 全球肝癌市場，膽管癌症，各地區(2018年～2030年)
- 肝芽腫
- 全球肝癌市場，肝芽腫各，各地區(2018年～2030年)
- 其他
- 全球肝癌市場，其他，各地區(2018年～2030年)
第6章 全球肝癌市場:各治療類型
- 主要調查結果
- 簡介
- 全球肝癌市場，各治療類型(2018年～2030年)
- 標的藥物療法
- 全球肝癌市場，標的藥物療法，各地區(2018年～2030年)
- 免疫療法
- 全球肝癌市場，免疫療法，各地區(2018年～2030年)
- 化療
- 全球肝癌市場，化療，各地區(2018年～2030年)
第7章 全球肝癌市場:各地區
- 主要調查結果
- 簡介
- 肝癌市場評估，各地區(2018年～2030年)
- 肝癌市場 - 北美
- 北美:肝癌市場，各治療類型(2018年～2030年)
- 北美:肝癌市場，各類型(2018年～2030年)
- 肝癌市場 - 美國
- 肝癌市場 - 加拿大
- 肝癌市場 - 歐洲
- 歐洲:肝癌市場，各治療類型(2018年～2030年)
- 歐洲:肝癌市場，各類型(2018年～2030年)
- 肝癌市場 - 英國
- 肝癌市場 - 法國
- 肝癌市場 - 德國
- 肝癌市場 - 義大利
- 肝癌市場 - 西班牙
- 肝癌市場 - 荷蘭
- 肝癌市場 - 俄羅斯
- 肝癌市場 - 亞太地區
- 亞太地區:肝癌市場，各治療類型(2018年～2030年)
- 亞太地區:肝癌市場，各類型(2018年～2030年)
- 肝癌市場 - 中國
- 肝癌市場 - 印度
- 肝癌市場 - 馬來西亞
- 肝癌市場 - 日本
- 肝癌市場 - 印尼
- 肝癌市場 - 韓國
- 肝癌市場 - 中東·非洲
- 中東·非洲:肝癌市場，各治療類型(2018年～2030年)
- 中東·非洲:肝癌市場，各類型(2018年～2030年)
- 肝癌市場 - 沙烏地阿拉伯
- 肝癌市場 - 阿拉伯聯合大公國
- 肝癌市場 - 以色列
- 肝癌市場 - 南非
- 肝癌市場 - 南美
- 南美:肝癌市場，各治療類型(2018年～2030年)
- 南美:肝癌市場，各類型(2018年～2030年)
- 肝癌市場 - 墨西哥
- 肝癌市場 - 巴西
- 肝癌市場 - 阿根廷
第8章 競爭情形
- 擴大·收購的分析
- 擴大
- 收購
- 夥伴關係/合作/協定/公開
第9章 企業簡介
- Abbott Laboratories
- Roche
- Bayer AG
- Bristol Myers Squibb Company
- Celsion Corporation
- Eisai Co.
- Exelixis
- Eli Lilly
- Qiagen N.V
- Merck
- Pfizer
- AbbVie
- Amgen
- Thermo Fisher Scientific
- AstraZeneca
- Johnson & Johnson
- Sanofi SA
- Novartis AG
The global liver cancer market size is expected to reach USD 10.48 billion by 2030, according to a new study by Polaris Market Research. The report "Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The main drivers influencing the market growth are the rising incidence of liver cancer, increased investments in research & development to create novel medicines, and government programmers to raise cancer awareness. For instance, the Globocan 2020 study estimates that approximately 905,677 new cases of liver cancer were detected worldwide.
Moreover, according to Cancer Research UK, there are around 6,200 new liver cancer cases in the UK each year, or 17 cases every day. With 2% of all new cancer cases, liver cancer is the 18th most prevalent malignancy in the UK. Liver cancer is the 20th most prevalent cancer in women in the UK, with about 2,100 new cases per year.
Additionally, the market is anticipated to rise due to rising research initiatives and funding, which might lead to the developing of an innovative liver cancer treatment if these studies have successful outcomes. For instance, according to Clinical Trial.gov, NETRIS Pharma and University Hospital, Grenoble collaborated to study on September 23, 2022, will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in the first-line setting in patients with unresectable hepatocellular carcinoma.
The NP137 study medication is being evaluated with atezolizumab-bevacizumab to improve tumor response and survival outcomes while maintaining acceptable safety. The trial officially began in November 2022 and is scheduled to end in November 2024.
Furthermore, a researcher from Australia's Edith Cowan University got USD 2.35 million in funding to support a new type of radiation treatment for liver cancer that will be trialed across Australia over the next five years. Due to the increasing prevalence of liver cancer and associated risk factors and continuous research and development efforts, the market is anticipated to rise rapidly throughout the forecast period.
But throughout the projection period, expansion in the market is anticipated to be constrained by elements including side effects linked to specific pharmaceuticals, the high price of cancer therapies, and strict regulatory environments.
Liver Cancer Market Report Highlights
In 2021, hepatocellular carcinoma is expected to rule the liver cancer market. Technological advancement, personalized medicine, and cost-effective treatment options are factors that are anticipated to boost the expansion of the global market for hepatocellular carcinoma treatments.
In 2021, the targeted medication therapy category will account for the greatest share of the market. Targeted therapy is proving to be a viable prospective treatment with promising therapeutic effects in a number of cancers.
In 2021, the North America accounted for the largest revenue share in 2021. The main factors influencing market expansion in North America are the rising incidence of liver cancer in the area, the presence of sizable market participants, and the development of novel products.
The global players with global presence include Abbott Laboratories, F. Hoffmann-La Roche, Bayer AG, Bristol Myers Squibb Company, and Celsion Corporation.
Polaris Market Research has segmented the Liver Cancer Market report based on, type, treatment type, and region:
Liver Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types
Liver Cancer, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)
Targeted Drug Therapy
Immunotherapy
Chemotherapy
Liver Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)
North America
U.S
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Liver Cancer Market Insights
- 4.1. Liver Cancer Market - Industry Snapshot
- 4.2. Liver Cancer Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing prevalence of liver cancer
- 4.2.1.2. Rising initiatives undertaken by public and private organizations
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost of diagnostic imaging
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Liver Cancer Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Liver Cancer Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Liver Cancer, by Type, 2018 - 2030 (USD Billion)
- 5.3. Hepatocellular Carcinoma
- 5.3.1. Global Liver Cancer Market, by Hepatocellular Carcinoma, by Region, 2018 - 2030 (USD Billion)
- 5.4. Cholangio Carcinoma
- 5.4.1. Global Liver Cancer Market, by Cholangio Carcinoma, by Region, 2018 - 2030 (USD Billion)
- 5.5. Hepatoblastoma
- 5.5.1. Global Liver Cancer Market, by Hepatoblastoma, by Region, 2018 - 2030 (USD Billion)
- 5.6. Others
- 5.6.1. Global Liver Cancer Market, by Others, by Region, 2018 - 2030 (USD Billion)
6. Global Liver Cancer Market, by Treatment Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 6.3. Targeted Drug Therapy
- 6.3.1. Global Liver Cancer Market, by Targeted Drug Therapy, by Region, 2018 - 2030 (USD Billion)
- 6.4. Immunotherapy
- 6.4.1. Global Liver Cancer Market, by Immunotherapy, by Region, 2018 - 2030 (USD Billion)
- 6.5. Chemotherapy
- 6.5.1. Global Liver Cancer Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)
7. Global Liver Cancer Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
- 7.3. Liver Cancer Market - North America
- 7.3.1. North America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.3.2. North America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.3.3. Liver Cancer Market - U.S.
- 7.3.3.1. U.S.: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.3.3.2. U.S.: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.3.4. Liver Cancer Market - Canada
- 7.3.4.1. Canada: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.3.4.2. Canada: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4. Liver Cancer Market - Europe
- 7.4.1. Europe: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.2. Europe: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.3. Liver Cancer Market - UK
- 7.4.3.1. UK: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.3.2. UK: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.4. Liver Cancer Market - France
- 7.4.4.1. France: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.4.2. France: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.5. Liver Cancer Market - Germany
- 7.4.5.1. Germany: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.5.2. Germany: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.6. Liver Cancer Market - Italy
- 7.4.6.1. Italy: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.6.2. Italy: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.7. Liver Cancer Market - Spain
- 7.4.7.1. Spain: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.7.2. Spain: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.8. Liver Cancer Market - Netherlands
- 7.4.8.1. Netherlands: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.8.2. Netherlands: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.4.9. Liver Cancer Market - Russia
- 7.4.9.1. Russia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.4.9.2. Russia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5. Liver Cancer Market - Asia Pacific
- 7.5.1. Asia Pacific: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.2. Asia Pacific: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.3. Liver Cancer Market - China
- 7.5.3.1. China: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.3.2. China: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.4. Liver Cancer Market - India
- 7.5.4.1. India: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.4.2. India: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.5. Liver Cancer Market - Malaysia
- 7.5.5.1. Malaysia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.5.2. Malaysia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.6. Liver Cancer Market - Japan
- 7.5.6.1. Japan: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.6.2. Japan: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.7. Liver Cancer Market - Indonesia
- 7.5.7.1. Indonesia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.7.2. Indonesia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.5.8. Liver Cancer Market - South Korea
- 7.5.8.1. South Korea: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.5.8.2. South Korea: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.6. Liver Cancer Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.6.2. Middle East & Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.6.3. Liver Cancer Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.6.3.2. Saudi Arabia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.6.4. Liver Cancer Market - UAE
- 7.6.4.1. UAE: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.6.4.2. UAE: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.6.5. Liver Cancer Market - Israel
- 7.6.5.1. Israel: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.6.5.2. Israel: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.6.6. Liver Cancer Market - South Africa
- 7.6.6.1. South Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.6.6.2. South Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.7. Liver Cancer Market - Latin America
- 7.7.1. Latin America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.7.2. Latin America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.7.3. Liver Cancer Market - Mexico
- 7.7.3.1. Mexico: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.7.3.2. Mexico: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.7.4. Liver Cancer Market - Brazil
- 7.7.4.1. Brazil: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.7.4.2. Brazil: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- 7.7.5. Liver Cancer Market - Argentina
- 7.7.5.1. Argentina: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- 7.7.5.2. Argentina: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Abbott Laboratories
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Roche
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Bristol Myers Squibb Company
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Celsion Corporation
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Eisai Co.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Exelixis
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Eli Lilly
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Qiagen N.V
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Merck
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Pfizer
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. AbbVie
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Amgen
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Thermo Fisher Scientific
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. AstraZeneca
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
- 9.16. Johnson & Johnson
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
- 9.17. Sanofi SA
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
- 9.18. Novartis AG
- 9.18.1. Company Overview
- 9.18.2. Financial Performance
- 9.18.3. Product Benchmarking
- 9.18.4. Recent Development
List of Tables
- Table 1 Global Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 2 Global Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 3 Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
- Table 4 North America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 5 North America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 6 U.S.: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 7 U.S.: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 8 Canada: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 9 Canada: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 10 Europe: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 11 Europe: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 12 UK: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 13 UK: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 14 France: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 15 France: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 16 Germany: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 17 Germany: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 18 Italy: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 19 Italy: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 20 Spain: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 21 Spain: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 22 Netherlands: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 23 Netherlands: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 24 Russia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 25 Russia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 26 Asia Pacific: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 27 Asia Pacific: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 28 China: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 29 China: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 30 India: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 31 India: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 32 Malaysia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 33 Malaysia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 34 Japan: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 35 Japan: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 36 Indonesia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 37 Indonesia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 38 South Korea: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 39 South Korea: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 40 Middle East & Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 41 Middle East & Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 42 Saudi Arabia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 43 Saudi Arabia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 44 UAE: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 45 UAE: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 46 Israel: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 47 Israel: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 48 South Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 49 South Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 50 Latin America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 51 Latin America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 52 Mexico: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 53 Mexico: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 54 Brazil: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 55 Brazil: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
- Table 56 Argentina: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
- Table 57 Argentina: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
List of Figures
Figure 1 Global Liver Cancer Market, 2018 - 2030 (USD Billion)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
Figure 4 Market by Geography
Figure 5 Porter's Five Forces
Figure 6 Market by Treatment Type
Figure 7 Global Liver Cancer Market, by Treatment Type, 2021 & 2030 (USD Billion)
Figure 8 Market by Type
Figure 9 Global Liver Cancer Market, by Type, 2021 & 2030 (USD Billion)
Figure 10 Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
Figure 11 Strategic Analysis - Liver Cancer Market
